The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

被引：0

作者：

Mutlu Hizal

Burak Bilgin

Nail Paksoy

Özgür Açıkgöz

Ahmet Sezer

Mustafa Gürbüz

Naziye Ak

Şebnem Yücel

Murat Ayhan

Cihan Erol

Aykut Demirkıran

Nil Molinas Mandel

Abdallah Shbair

İvo Gökmen

Tuğba Başoğlu

Semra Paydaş

Atike Gökçen Demiray

Yakup İriağaç

Teoman Şakalar

Esra Zeynelgil

Ali Murat Tatlı

Aykut Bahçeci

Deniz Can Güven

Burcu Caner

Alper Can

Ahmet Gülmez

Yusuf Karakaş

Bülent Yalçın

Ahmet Demirkazık

Ahmet Bilici

Adnan Aydıner

Perran Fulden Yumuk

Mehmet Ali Nahit Şendur

机构：

[1] Ankara City Hospital,Department of Medical Oncology

[2] Atatürk Chest Disease and Chest Surgery Research and Education Hospital,Department of Medical Oncology

[3] İstanbul University, Department of Medical Oncology, İstanbul Faculty of Medicine

[4] Medipol University,Department of Medical Oncology

[5] Faculty of Medicine,Department of Medical Oncology

[6] Başkent University,Department of Medical Oncology

[7] Faculty of Medicine,Department of Medical Oncology

[8] Ankara University,Department of Medical Oncology

[9] Faculty of Medicine,Department of Medical Oncology

[10] Yozgat City Hospital,Department of Medical Oncology, Meram Faculty of Medicine

[11] Kartal Lütfi Kırdar City Hospital,Department of Medical Oncology

[12] Yıldırım Beyazıt University Faculty of Medicine,Department of Medical Oncology

[13] Necmeddin Erbakan University,Department of Medical Oncology, Faculty of Medicine

[14] American Hospital,Division of Medical Oncology

[15] Bezmialem University Faculty of Medicine,Department of Medical Oncology

[16] Trakya University,Department of Medical Oncology

[17] Marmara University School of Medicine,Department of Medical Oncology

[18] Çukurova University Faculty of Medicine,Department of Medical Oncology

[19] Pamukkale University Faculty of Medicine,Department of Medical Oncology

[20] Namık Kemal University Faculty of Medicine,Department of Medical Oncology

[21] Necip Fazıl City Hospital,Department of Medical Oncology

[22] Dışkapı Education and Research Hospital,Department of Medical Oncology

[23] Akdeniz University Faculty of Medicine,Department of Medical Oncology

[24] Ersin Arslan Education and Research Hospital,Department of Medical Oncology

[25] Hacettepe University Faculty of Medicine,Department of Medical Oncology

[26] Uludağ University Faculty of Medicine,Department of Medical Oncology

[27] İstinye University Faculty of Medicine,undefined

[28] İnönü University Faculty of Medicine,undefined

[29] Bodrum Acıbadem Hospital,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷

关键词：

Osimertinib; Non-small cell lung cancer; EGFR; T790M; Second line;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1501 / 1508

页数：7

共 50 条

[41] Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation
Hu, Xueyang
Chen, Wenjun
Li, Xiaoqiu
Zhao, Chenchen
Zhang, Congjun
Xiong, Fuxing
Wu, Hongyang
ANNALS OF PALLIATIVE MEDICINE, 2019, 8 (05) : 525 - 531
[42] Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Pereira, Isabel
Gaspar, Catia
Pina, Marta
Azevedo, Isabel
Rodrigues, Ana
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (12)
[43] Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples
Kiura, Katsuyuki
Yoh, Kiyotaka
Katakami, Nobuyuki
Nogami, Naoyuki
Kasahara, Kazuo
Takahashi, Toshiaki
Okamoto, Isamu
Cantarini, Mireille
Hodge, Rachel
Uchida, Hirohiko
CANCER SCIENCE, 2018, 109 (04) : 1177 - 1184
[44] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
Kazuhisa Nakashima
Yuichi Ozawa
Haruko Daga
Hisao Imai
Motohiro Tamiya
Takaaki Tokito
Takahisa Kawamura
Hiroaki Akamatsu
Yuko Tsuboguchi
Toshiaki Takahashi
Nobuyuki Yamamoto
Keita Mori
Haruyasu Murakami
Investigational New Drugs, 2020, 38 : 1854 - 1861
[45] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
Nakashima, Kazuhisa
Ozawa, Yuichi
Daga, Haruko
Imai, Hisao
Tamiya, Motohiro
Tokito, Takaaki
Kawamura, Takahisa
Akamatsu, Hiroaki
Tsuboguchi, Yuko
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Mori, Keita
Murakami, Haruyasu
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1854 - 1861
[46] Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, Biagio
Baglivo, Sara
Paglialunga, Luca
De Giglio, Andrea
Bellezza, Guido
Chiari, Rita
Crino, Lucio
Metro, Giulio
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (06) : 387 - 403
[47] Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation
Miyashita, Yosuke
Ko, Ryo
Shimada, Naoko
Mitsuishi, Yoichiro
Miura, Keita
Matsumoto, Naohisa
Asao, Tetsuhiko
Shukuya, Takehito
Shibayama, Rina
Koyama, Ryo
Takahashi, Kazuhisa
THORACIC CANCER, 2021, 12 (03) : 329 - 338
[48] Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
John, Thomas
Bowden, Jeffrey J.
Clarke, Stephen
Fox, Stephen B.
Garrett, Kerryn
Horwood, Keith
Karapetis, Christos S.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 296 - 303
[49] Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
Chang, Gee-Chen
Shih, Jin-Yuan
Yu, Chong-Jen
Chao, Heng-Sheng
Yang, Cheng-Ta
Lin, Chien-Chung
Hung, Jen-Yu
Hsiao, Sheng-Yen
Wang, Chin-Chou
Chian, Chih-Feng
Hsia, Te-Chun
Chen, Yuh-Min
PLOS ONE, 2024, 19 (05):
[50] Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang
Shundong Cang
Delong Liu
Journal of Hematology & Oncology, 9

← 1 2 3 4 5 →